Harry Shuman Sells 6,000 Shares of Merus (NASDAQ:MRUS) Stock

Merus (NASDAQ:MRUSGet Free Report) VP Harry Shuman sold 6,000 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $52.89, for a total transaction of $317,340.00. Following the transaction, the vice president now directly owns 7,002 shares in the company, valued at $370,335.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Merus Stock Performance

NASDAQ MRUS opened at $52.90 on Friday. The firm has a 50-day simple moving average of $46.41 and a 200 day simple moving average of $39.41. Merus has a twelve month low of $19.81 and a twelve month high of $61.61. The stock has a market cap of $3.10 billion, a PE ratio of -19.10 and a beta of 1.10.

Merus (NASDAQ:MRUSGet Free Report) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. The business had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $8.94 million. Research analysts forecast that Merus will post -3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRUS has been the topic of several analyst reports. William Blair reissued an “outperform” rating on shares of Merus in a research report on Monday, April 22nd. BMO Capital Markets increased their target price on shares of Merus from $84.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday. Stifel Nicolaus increased their target price on shares of Merus from $65.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Truist Financial increased their target price on shares of Merus from $69.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of Merus in a report on Friday, May 24th. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Merus presently has an average rating of “Moderate Buy” and a consensus price target of $72.70.

View Our Latest Stock Analysis on MRUS

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC lifted its stake in Merus by 37.7% during the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 343 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Merus by 64.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock worth $58,000 after buying an additional 828 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Merus during the first quarter worth approximately $72,000. SG Americas Securities LLC acquired a new stake in shares of Merus during the first quarter worth approximately $108,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Merus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,459 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.

About Merus

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Read More

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.